BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

WHO validates China's Convidecia as 11th vaccine for COVID-19

May 20, 2022 | News

Convidecia is a genetically engineered vaccine with the replication-defective adenovirus type 5 vector that expresses the SARS-CoV-2 coronavirus spike protein



The World Health Organization (WHO) has issued an emergency use listing (EUL) for Convidecia, a vaccine manufactured by CanSino Biologics, China, adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19 caused by SARS-CoV-2.

In addition to shortening the vaccination cycle by leveraging the advantages of its single-dose regimen, Convidecia can be stably transported and stored between 2°C and 8°C, making it more accessible to developing countries with insufficient storage facilities and medical resources, reducing the burden placed on healthcare systems and medical workers, and contributing to building broad immune protection globally.

Currently, CanSinoBIO's Convidecia has received approvals in more than 10 markets: China, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Pakistan, United Arab Emirates, Indonesia and Malaysia. The company also established local partnerships for distribution in various countries, including setting up fill-and-finish facilities in Mexico, Pakistan, and Malaysia, allowing its COVID-19 vaccine access to more people in developing markets.

So far, it has been approved as a heterologous booster vaccine in China, Argentina, Malaysia and Indonesia. It is also the first and only adenovirus-vectored vaccine to be included in the heterologous vaccination programme in China.